Comparison of CR + CRP rates with mylotarg and high-dose ara-C.
| First CR Duration . | 3 months - < 1 year . | > 1 year . | ||
|---|---|---|---|---|
| . | Pts . | % CR . | Pts . | % CR . |
| Ara-C1 | 95 | 20 | 71 | 63 |
| Mylotarg | 80 | 28 | 62 | 32 |
| First CR Duration . | 3 months - < 1 year . | > 1 year . | ||
|---|---|---|---|---|
| . | Pts . | % CR . | Pts . | % CR . |
| Ara-C1 | 95 | 20 | 71 | 63 |
| Mylotarg | 80 | 28 | 62 | 32 |
ara-C ≥ 0.5 gm/m2/dose +/- fludarabine or anthracyclines as given to M.D. Anderson patients with AML in untreated first relapse 1990-1999. Patients selected to meet eligibility criteria of mylotarg protocol.